JG
RPRX

Jefferies Group’s Repros Therapeutics Inc. RPRX Stock Holding History

Jefferies Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-9,800
Closed -$31.5K – 2856
2015
Q3 		$73K Buy
+9,800
New +$74.9K ﹤0.01% 2075
2013
Q3 		– Sell
-4,815
Closed -$103K – 2484
2013
Q2 		$89K Buy
+4,815
New +$85K ﹤0.01% 1654

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jefferies Group's RPRX Position: Q4 2015 in Review

Jefferies Group sold out of Repros Therapeutics Inc. (RPRX) in Q4 2015, closing a stake of 9,800 shares — an estimated $31.5K sold.

Jefferies Group first reported a position in RPRX in Q2 2013 and held it in 2 quarters. The position peaked at $89K in Q2 2013. 56 funds tracked by Wall St. Rank hold RPRX as of Q4 2015.

  • Jefferies Group reported no remaining Repros Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
  • Jefferies Group sold 9,800 Repros Therapeutics Inc. shares in Q4 2015, an estimated $31.5K.
  • Jefferies Group first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 2 quarters.
  • Jefferies Group's Repros Therapeutics Inc. position peaked at $89K in Q2 2013.
  • 56 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2015.

Based on Jefferies Group's 13F filing for Q4 2015, filed 12 Feb 2016.